Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response?
Lejla Alić(Erasmus MC), Wiro J. Niessen(Amsterdam Neuroscience), M. van Vliet(Erasmus MC), Jifke F. Veenland(Erasmus MC), Alexander M.M. Eggermont(University Medical Center Utrecht), Cornelis F. van Dijke(Erasmus MC)
Cited by 95
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k